<div id="readability-page-1"><p><span>Bristol Myers Squibb (NYSE:BMY - Get Free Report)</span>'s stock had its &#34;buy&#34; rating reaffirmed by stock analysts at Guggenheim in a report released on Wednesday,Benzinga reports. They presently have a $72.00 price target on the biopharmaceutical company's stock. Guggenheim's target price indicates a potential upside of 24.82% from the stock's current price.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li></ul><p>Several other research analysts have also commented on the company. Wells Fargo &amp; Company  restated an &#34;outperform&#34; rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, January 13th. Bank of America raised Bristol Myers Squibb from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, February 6th. Finally, Piper Sandler  reiterated an &#34;overweight&#34; rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, twelve have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $61.35.</p><p><b>Get Our Latest Stock Report on Bristol Myers Squibb</b></p><h2>Bristol Myers Squibb Price Performance</h2><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Shares of BMY opened at $57.68 on Wednesday. The firm has a 50-day simple moving average of $59.51 and a two-hundred day simple moving average of $52.94. The stock has a market cap of $117.77 billion, a PE ratio of 16.72, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. </p><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. During the same period in the previous year, the business posted $1.67 EPS. The business's revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.  As a group, analysts forecast that  Bristol Myers Squibb will post 6.74 EPS for the current year. </p><h2>Insiders Place Their Bets</h2><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p>In related news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by corporate insiders. </p><h2>Hedge Funds Weigh In On Bristol Myers Squibb</h2><p>Hedge funds have recently made changes to their positions in the company. J. Derek Lewis &amp; Associates Inc. purchased a new stake in shares of  Bristol Myers Squibb in the 4th quarter valued at about $432,000.  Osbon Capital Management LLC acquired a new position in  Bristol Myers Squibb during the fourth quarter worth approximately $55,000.  World Investment Advisors boosted its holdings in shares of  Bristol Myers Squibb by 14.1% in the fourth quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company's stock valued at $3,478,000 after acquiring an additional 7,977 shares during the period.  Nalls Sherbakoff Group LLC purchased a new position in shares of  Bristol Myers Squibb during the fourth quarter worth approximately $92,000.  Finally, Larry Mathis Financial Planning LLC acquired a new position in shares of  Bristol Myers Squibb in the 4th quarter valued at $427,000. Hedge funds and other institutional investors own  76.41% of the company's stock. </p><h2>Bristol Myers Squibb Company Profile</h2> (Get Free Report)<p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.  </p><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Guggenheim has reaffirmed a "buy" rating for Bristol Myers Squibb (NYSE:BMY) with a price target of $72.00, indicating a potential upside of 24.82%. Other analysts have also raised their price targets, with a consensus rating of "Hold" and an average target of $61.35. The stock opened at $57.68, with a market cap of $117.77 billion. Bristol Myers Squibb reported $1.26 EPS for the last quarter, missing estimates, but revenue was $12.50 billion, exceeding expectations. The company has set FY 2026 guidance at 6.050-6.350 EPS.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Bristol Myers Squibb

Health Care Select Sector SPDR

VG Health

iShares US Pharma

ProShares Ultra Health Care ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Direxion Pharma & Medical Bull 3X

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Bristol-Myers Squibb Company

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Bristol Myers Squibb (NYSE:BMY) Earns Buy Rating from Guggenheim